Anke Biotechnology's CD7-Targeted CAR-T Therapy PA3-17 Injection on Track for pre-NDA Submission in Q1 2027

Source: Securities Times

People's Finance News, November 12thANKEBIO(300009) stated yesterday during an institutional investor meeting that the PA3-17 injection from its participating company, Bo sheng ji medicine science and technology (suzhou) co., LTD, has been designated as a breakthrough therapy and entered the critical phase of clinical trial stage II. The company aims to complete enrollment of all patients within one year and expects to submit a pre-NDA communication application in the first quarter of 2027. In terms of indication expansion, an application for pediatric indications is currently being submitted. In the future, after the approval of T-ALL/LBL indications, Bo sheng ji will expand into other indications including peripheral T-cell lymphoma, NKT-cell lymphoma, and acute myeloid leukemia.